Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population

被引:0
|
作者
Gallegos-Arreola, M. P. [1 ]
Garcia Verdin, P. M. [1 ]
Magana-Torres, M. T. [1 ]
Figuera, L. E. [1 ,2 ]
Zuniga-Gonzalez, G. M. [3 ]
Rosales-Reynoso, M. A. [3 ]
Gomez-Meda, B. C. [4 ]
Puebla-Perez, A. M. [5 ]
机构
[1] Inst Mexicano Seguro Social, Ctr Invest Biomed Occidente, Div Genet, Guadalajara, Jalisco, Mexico
[2] Univ Guadalajara, Ctr Univ Ciencias Salud, Doctorado Genet Humana, Guadalajara, Jalisco, Mexico
[3] Inst Mexicano Seguro Social, Ctr Invest Biomed Occidente, Div Med Mol, Guadalajara, Jalisco, Mexico
[4] Univ Guadalajara, Ctr Univ Ciencias Salud, Inst Genet Humana Dr Enrique Corona Rivera, Dept Biol Mol & Genom, Guadalajara, Jalisco, Mexico
[5] Univ Guadalajara, Ctr Univ Ciencias Exactas & Ingn, Lab Inmunofarmacol, Guadalajara, Jalisco, Mexico
关键词
Breast cancer; KRAS; Rs61764370; Rs9266; Rs1400; 80026; Polymorphism; Mexican; LET-7; MICRORNA-BINDING; RS712; POLYMORPHISM; 3'-UNTRANSLATED REGION; OVARIAN-CANCER; LUNG-CANCER; VARIANT; SITE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Polymorphisms of the KRAS gene have been shown to be associated with cancer. However, their association with breast cancer (BC) has been inconsistent. The purpose of this study was to determine the frequency with which the rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene are associated with BC in patients of the Mexican population. PATIENTS AND METHODS: The rs61764370 A>C or T>G and rs140080026 A>G polymorphisms were determined by Polymerase Chain Reaction (PCR), and the rs9266 A>G polymorphism was determined by DNA sequencing of healthy Mexican subjects and BC patients. RESULTS: We observed that 78% of BC patients are overweight and/or obese, 57% have metastatic lymph nodes, 64% have luminal A/B cancer subtypes, and 61% have stage III-IV cancer. The rs61764370 polymorphism was associated with BC susceptibility when the BC patients and the control group were compared for the AC genotype (p= 0.020), AC vs. AA genotypes (heterozygous model: p= 0.016), AC/CC genotype (dominant model: p= 0.002), and the C allele (p= 0.007). The AC/CC genotype (p= 0.018; rs61764370) and AG/GG genotype (p= 0.005; rs9266) were associated with age in BC patients >= 50 years old. The AC/CC (rs61764370) and AG/ GG (rs9266) genotypes were classified by molecular subtype, TNM stage, miscarriage, lymph node metastasis, ductal type, and Ki-67. These classifications were also associated with BC patients, indicating that these factors may significantly contribute to BC risk. The AAA (OR 0.65, 95% CI 0.43-0.98, p= 0.039) and CAA (OR 3.25, 95% CI 1.13-9.36, p= 0.021) haplotypes were also associated with BC susceptibility. In addition, 94 polymorphisms were identified on the 3'UTR of the KRAS gene GRCh 38/hg3 (25,209,490-25,209,122) in BC (n =112) and control (n =113) samples. However, 92 of these polymorphisms have only expressed the major allele (wild-type allele). CONCLUSIONS: The rs61764370 polymorphism in the KRAS gene was associated with BC susceptibility in the Mexican population. The dominant model of the rs61764370 and rs9266 polymorphisms (classified by molecular subtype, miscarriage, TNM stage, lymph node metastasis, and Ki-67) could significantly contribute to BC risk in patients >= 50 years. The CAA haplotype could significantly contribute to BC risk in the Mexican population analyzed.
引用
收藏
页码:6454 / 6464
页数:11
相关论文
共 50 条
  • [1] Association between KRAS rs61764370 and triple-negative breast cancer-a false positive?
    Pharoah, Paul
    Antoniou, Antonis
    Berchuck, Andrew
    Chenevix-Trench, Georgia
    Gayther, Simon
    Goode, Ellen
    Milne, Roger
    Sellers, Tom
    Tyrer, Jonathan
    LANCET ONCOLOGY, 2011, 12 (08): : 723 - 724
  • [2] No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
    Hollestelle, Antoinette
    van der Baan, Frederieke H.
    Berchuck, Andrew
    Johnatty, Sharon E.
    Aben, Katja K.
    Agnarsson, Bjarni A.
    Aittomaki, Kristiina
    Alducci, Elisa
    Andrulis, Irene L.
    Anton-Culver, Hoda
    Antonenkova, Natalia N.
    Antoniou, Antonis C.
    Apicella, Carmel
    Arndt, Volker
    Arnold, Norbert
    Arun, Banu K.
    Arver, Brita
    Ashworth, Alan
    Baglietto, Laura
    Balleine, Rosemary
    Bandera, Elisa V.
    Barrowdale, Daniel
    Bean, Yukie T.
    Beckmann, Lars
    Beckmann, Matthias W.
    Benitez, Javier
    Berger, Andreas
    Berger, Raanan
    Beuselinck, Benoit
    Bisogna, Maria
    Bjorge, Line
    Blomqvist, Carl
    Bogdanova, Natalia V.
    Bojesen, Anders
    Bojesen, Stig E.
    Bolla, Manjeet K.
    Bonanni, Bernardo
    Brand, Judith S.
    Brauch, Hiltrud
    Brenner, Hermann
    Brinton, Louise
    Brooks-Wilson, Angela
    Bruinsma, Fiona
    Brunet, Joan
    Bruning, Thomas
    Budzilowska, Agnieszka
    Bunker, Clareann H.
    Burwinkel, Barbara
    Butzow, Ralf
    Buys, Saundra S.
    GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 386 - 401
  • [3] rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis
    Zhang, Shi-Yan
    Shi, Jing
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) : 699 - 704
  • [4] KRAS rs61764370 in Epithelial Ovarian Cancer-Response
    Risch, Harvey A.
    Berchuck, Andrew
    Pharoah, Paul D. P.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6601 - 6601
  • [5] KRAS rs61764370 in Epithelial Ovarian Cancer-Letter
    Weidhaas, Joanne B.
    Slack, Frank J.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6600 - 6600
  • [6] Association between KRAS rs61764370 and triple-negative breast cancer-a false positive? reply
    Weidhaas, Joanne
    Slack, Frank
    Miller, Nicola
    Harris, Lyndsay
    Tuck, David
    Zhu, Yong
    Zelterman, Daniel
    Kerin, Michael
    Paranjape, Trupti
    Heneghan, Helen
    Lindner, Robert
    Keane, Florence
    Dorairaj, Jemima
    Geyda, Kimberly
    Pelletier, Cory
    Nallur, Sunitha
    LANCET ONCOLOGY, 2011, 12 (08): : 724 - 724
  • [7] Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing
    Berchuck, A.
    Pharoah, P.
    Ramus, S.
    Gayther, S.
    Palmieri, R.
    Pearce, C.
    Couch, F.
    Antonio, A.
    Goode, E.
    Schildkraut, J.
    Chenevix-Trench, G.
    Sellers, T.
    Risch, H.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : S2 - S3
  • [8] Association of rs2234693 and rs9340799 polymorphisms of ESR1 gene in breast cancer of Mexican population
    Ivette Carrillo-Moreno, Dalia
    Eduardo Figuera, Luis
    Zuniga-Gonzalez, Guillermo M.
    Maria Puebla-Perez, Ana
    de Jesus Moran-Mendoza, Andres
    Patricia Gallegos-Arreola, Martha
    JOURNAL OF BUON, 2019, 24 (05): : 1927 - 1933
  • [9] The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing
    Pharoah, Paul D. P.
    Palmieri, Rachel T.
    Ramus, Susan J.
    Gayther, Simon A.
    Andrulis, Irene L.
    Anton-Culver, Hoda
    Antonenkova, Natalia
    Antoniou, Antonis C.
    Goldgar, David
    Beattie, Mary S.
    Beckmann, Matthias W.
    Birrer, Michael J.
    Bogdanova, Natalia
    Bolton, Kelly L.
    Brewster, Wendy
    Brooks-Wilson, Angela
    Brown, Robert
    Butzow, Ralf
    Caldes, Trinidad
    Caligo, Maria Adelaide
    Campbell, Ian
    Chang-Claude, Jenny
    Chen, Y. Ann
    Cook, Linda S.
    Couch, Fergus J.
    Cramer, Daniel W.
    Cunningham, Julie M.
    Despierre, Evelyn
    Doherty, Jennifer A.
    Doerk, Thilo
    Duerst, Matthias
    Eccles, Diana M.
    Ekici, Arif B.
    Easton, Douglas
    Fasching, Peter A.
    de Fazio, Anna
    Fenstermacher, David A.
    Flanagan, James M.
    Fridley, Brooke L.
    Friedman, Eitan
    Gao, Bo
    Sinilnikova, Olga
    Gentry-Maharaj, Aleksandra
    Godwin, Andrew K.
    Goode, Ellen L.
    Goodman, Marc T.
    Gross, Jenny
    Hansen, Thomas V. O.
    Harnett, Paul
    Rookus, Matti
    CLINICAL CANCER RESEARCH, 2011, 17 (11) : 3742 - 3750
  • [10] The rs1008562, rs2234671, and rs3138060 polymorphisms of the CXCR1 gene are associated with breast cancer risk in a Mexican population
    Gallegos-Arreola, M. P.
    Briseno-Zuno, C. J.
    Figuera, L. E.
    Sanchez-Lopez, J. Y.
    Zuniga-Gonzalez, G. M.
    Puebla-Perez, A. M.
    Gomez-Meda, B. C.
    Montoya-Fuentes, H.
    Delgado-Saucedo, J. I.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (19) : 9990 - 10002